First treatment activity and outcome of radioiodine therapy in thyroid cancer patients with metastases in lymph nodes: Mathematical correlation and clinical implications

Experimental Oncology

Volumn 28, Issue 1, 2006, Pages 75-79

  Kozak, O V ^b   Muzichenko, L V ^b   Trembach, A M ^a   Voit, N U ^a   Turicina, V V ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Regional Oncological Center   (Ukraine)

Author keywords

131I; Kinetics; Metastases; Thyroid cancer

Indexed keywords

IODINE 131;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME;

ADENOMA; AGED; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MIDDLE AGED; MODELS, THEORETICAL; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 33646061637     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ain KB. Treatment of thyroid cancer. In: Diseases of the thyroid. Lewis E. Bravermann, ed. New Jersey: Humana Press, 2000; pp. 287-317.
2. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnants ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89: 1666-73.
3. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984; 25: 1287-93.
4. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987; 12: 500-2.
5. Hoelzer S, Steiner D, Bauer R, Reiners C, Farahati J, Hundahl SA, Dudeck J. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med 2000; 27: 1465-72.
6. Hung GU, Tu ST, Wu IS, Yang KT. Comparison of the effectiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants. Jpn J Clin Oncol 2004; 34: 469-71.
7. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnants ablation rates. Nucl Med Commun 2003; 24: 489-95.
8. 131I therapeutic activity evaluation on the basis of mathematical analysis of diagnostic scintigraphy for differentiated thyroid cancer patients. Edhokrynologia 2001; 6: 76-9.
9. Logue JP, Tsang RW, Brierley JD, Simpson WJ. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 1994; 67: 1127-31.
10. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937-41.
11. 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-71.
12. O'Connell ME, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radiation therapy. Dose-response relationship in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993; 28: 16-26.
13. Schlumberger M, Pacini F. Thyroid tumors. Paris, 1999; 301.
14. Snyder J, Gorman C, Scanlon P. Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med 1983; 24: 659-65.
15. Verkooijen RB, Stokkel MP, Smit JW, Pauwels EK. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging 2004; 31: 499-506.